

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Ludwig Institute for Cancer Research	12/03/2007
Licentia Ltd.	12/07/2007
Seppo Yla-Herttuala	12/12/2007
RECEIVING PARTY DATA	
Name:	Vegenics Limited
Street Address:	Level 1, 10 Wallace Ave.
City:	Toorak, Victoria
State/Country:	AUSTRALIA
Postal Code:	3142
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	6958147
Application Number:	11064769
CORRESPONDENCE DATA	
Fax Number:	(312)474-0448
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	3124746300
Email:	docket@marshallip.com
Correspondent Name:	Marshall, Gerstein & Borun LLP
Address Line 1:	233 South Wacker Drive
Address Line 2:	6300 Sears Tower
Address Line 4:	Chicago, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	31265/G1000
NAME OF SUBMITTER:	David A. Gass

CH \$80.00 6958147

Total Attachments: 6

source=seppo#page1.tif

source=seppo#page2.tif

source=seppo#page3.tif

source=seppo#page4.tif

source=seppo#page5.tif

source=seppo#page6.tif

Assignment of Patent And Other Intellectual Property Rights

ASSIGNMENT OF PATENT AND OTHER INTELLECTUAL PROPERTY RIGHTS

BETWEEN

Ludwig Institute for Cancer Research
a Swiss not-for-profit Corporation
601 Third Street
New York, New York 10158

AND

Licentia Ltd.
Tukholmankatu 8A
FI-00290 Helsinki
Finland

AND

Seppo Yla-Herttuala
of University of Kuopio
A.I. Virtanen Institute, P.O. Box 1627
FI-70211 Kuopio
Finland

(collectively ASSIGNOR):

AND

Vegenics Limited
Level 1, 10 Wallace Ave
Toorak, Victoria 3142
Australia

(ASSIGNEE)

WHEREAS ASSIGNOR is collectively the owner(s) of the entire right, title and interest in the following INTELLECTUAL PROPERTY:

invention(s) or improvement(s) disclosed in applications for Letters Patent of the United States or other countries that are listed in the attached PATENT SCHEDULE; and

said applications listed on the PATENT SCHEDULE, and any and all other applications, both United States and in other countries (including but not limited to WIPO/PCT international applications, European regional or national applications, Australian applications, Canadian applications, and Japanese

Assignment of Patent And Other Intellectual Property Rights

applications), which ASSIGNOR, the inventors, or other predecessor in interest may file or have filed or be named as applicant(s) or inventor(s), either solely or jointly with others, on said invention or improvements; and

any and all Letters Patent of the United States and other countries, which may be obtained on any of said applications, including but not limited to patents listed on the PATENT SCHEDULE; and

in any reissue or extension thereof;

WHEREAS ASSIGNOR has agreed (pursuant to the terms of one or more executed written agreements, including a LICENSE AGREEMENT dated 25 April 2006 between Ludwig Institute for Cancer Research, Licentia Ltd., and Vegenics Ltd.) to assign its entire right, title, and interest in the INTELLECTUAL PROPERTY to Vegenics Limited, Level 1, 10 Wallace Ave, Toorak, 3142 Victoria, Australia (ASSIGNEE) with an effective date of April 2, 2007;

NOW, THEREFORE, for \$10.00 (Ten Dollars) and other good and valuable consideration, including consideration defined in other agreement(s) between the parties (such as the LICENSE AGREEMENT), ASSIGNOR hereby assigns to ASSIGNEE, its successors and assigns, ASSIGNOR's entire right, title and interest in the INTELLECTUAL PROPERTY. This assignment is an assignment *nunc pro tunc* (retroactively effective) with effective date of April 2, 2007.

This assignment includes the right of ASSIGNOR to apply for and obtain patents for the INTELLECTUAL PROPERTY; and the rights of ASSIGNOR to bring suit and to claim and retain any damages or other remedies for infringement (including past infringement) of the INTELLECTUAL PROPERTY.


ASSIGNOR warrants that ASSIGNOR is the owner of the interest herein assigned; that ASSIGNOR has the right to make this assignment; that the undersigned has the authority to bind the ASSIGNOR entity whose name appears with the signature of the undersigned and act on behalf of said ASSIGNOR entity; and that there are no outstanding prior assignments, licenses (except as recognized in Section 2.5 of the LICENSE

Assignment of Patent And Other Intellectual Property Rights



AGREEMENT), or other rights in the interest herein assigned, except in favor of ASSIGNEE.

ASSIGNOR agrees to provide such further assistance as necessary and reasonably requested by ASSIGNEE, including signing of additional documents, to give effect to this assignment and to facilitate the recordal of ASSIGNEE as owner of the INTELLECTUAL PROPERTY in any jurisdiction and on any relevant register of patent or other intellectual property rights.


WITNESS my hand this 3rd day of December, 2007.


Edward A. McDermott
President



Ludwig Institute for Cancer Research
a Swiss not-for-profit corporation
601 Third Street
New York, New York 10158

Witnesses: 1) 
Name: JONATHAN SKIRPER
2) 
Name:


WITNESS my hand this 5 day of December, 2007.


Markku Jalkanen
Acting CEO



Licentia Ltd.
Tukholmankatu 8A
FI-00290 Helsinki
Finland

Witnesses: 1) 
Name: CHARLOTTA HEIKINARO
2) 
Name: MARJA JANTUNEN

WITNESS my hand this 7 day of December, 2007.



Jyrki Ingman
Controller



Licentia Ltd.
Tukholmankatu 8A
FI-00290 Helsinki
Finland

Witnesses: 1) 
Name: CHARLOTTA HEIKINARO
2) 
Name: MARJA JANTUNEN

Assignment of Patent And Other Intellectual Property Rights

WITNESS my hand this 12th day of December, 2007.


Seppo Ylä-Herttuala

Witnesses: 1) 
Name: CHARLOTTA HEIKINAO
2) 
Name: MARIJA JERNSTROM

Assignment of Patent And Other Intellectual Property Rights

PATENT SCHEDULE

Pending Applications

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
35061A	5581.1	CA	2,340,593	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	10/22/1999
35061A	5581.1	JP	2000578021	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	10/22/1999
35061A	5581.1	PCT	PCT/US99/24054	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	10/22/1999

Issued Patents

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
35061A	5581.1	AT	0275417	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	AU	768330	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	7/8/2004
35061A	5581.1	BE	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	CH/LI	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	DE	69920031	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/22/2005
35061A	5581.1	DK	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	EPO	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	09/8/2004
35061A	5581.1	ES	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	FI	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	FR	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	GB	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	GR	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	IE	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	IT	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	NL	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004

Assignment of Patent And Other Intellectual Property Rights

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
35061A	5581.1	PT	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A	5581.1	SE	1126870	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	9/8/2004
35061A2	5581.1	US	6,958,147	Use of VEGF-C to Prevent Restenosis	10/25/2005